Register Login

Replimune Group Inc (REPL)

  • Event
  • May 19, 2022, 12:10 UTC

(75% Positive) REPLIMUNE GROUP, INC. (REPL) Announces Enrollment Update for results Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 1, 2025, 9:20 p.m.

    📋 REPLIMUNE GROUP, INC. (REPL) - Clinical Trial Update

    Filing Date: 2022-05-19

    Accepted: 2022-05-19 08:10:13

    Event Type: Clinical Trial Update

    Event Details:

    Replimune Group Inc (REPL) Announces Clinical Trial Update Replimune Group Inc (REPL) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, data
    • Diseases/Conditions: RP2/RP3 in HCC, colorectal cancer (CRC)
    • Clinical Stage: Phase 2, clinical trial
    • Collaboration: Replimune Group, Inc.
    • Updated Timeline: early 2023
      • expected in late 2022

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Replimune Group Inc
    • CIK: 0001737953
    • Ticker Symbol: REPL
    • Period End Date: 2022-05-19
    • Document Type: 8-K

Search

News categories